Bulk Pharmaceutical API Sources for ADRIAMYCIN PFS

Bulk Pharmaceutical API Sources for ADRIAMYCIN PFS

Vendor	Vendor Homepage	Vendor Sku	API Url
Sigma-Aldrich		D1515_SIGMA
Sigma-Aldrich		44583_SIGMA
Molport		MolPort-003-933-100
Amadis Chemical		A817779
AKos Consulting & Solutions		AKOS007930231
Oakwood Products		021790

Bulk Active Pharmaceutical Ingredient (API) Sources for ADRAIYCIN PFS

Last updated: February 20, 2026

Summary:
Adriamycin PFS (PFS: Premixed Freeze-Dried Powder) contains doxorubicin hydrochloride as its active ingredient. The primary sources for bulk doxorubicin hydrochloride include manufacturing companies with licensed production facilities aligned with regulatory standards like FDA, EMA, and equivalent agencies. Supply chain transparency and regulatory approvals influence source choices.

Major API Manufacturers for Doxorubicin Hydrochloride

Manufacturer	Country	Certification	Annual Production Capacity	Notable Points
Pfizer (Pfizer Oncology)	United States	FDA-approved	>1,000 kg/year	Original innovator; maintains supply chain control
Hikma Pharmaceuticals	Jordan	MHRA, FDA	~600 kg/year	Exporter of APIs to global markets
Sun Pharma	India	USFDA, EMA	~800 kg/year	Diversified API portfolio
Asegra Pharma (AstraZeneca’s legacy)	United States/Europe	EMA, FDA	Data not publicly available	Focuses on oncology APIs
Huons Co., Ltd.	South Korea	KFDA	Estimated 200–400 kg/year	Increasing presence in global markets
Teva Pharmaceutical Industries	Israel	FDA, EMA	Data unavailable	Broad generic API portfolio

Regulatory Considerations Influencing API Sourcing

• Quality Standards: Supplies must meet USP, EP, or JP standards for pharmaceutical use.
• Regulatory Approvals: Manufacturers possessing approved Drug Master Files (DMFs) or Certificates of Suitability (CEP) facilitate market access.
• Supply Chain Stability: Diversification reduces risk; reliance on a single source can hamper supply continuity.
• Pricing and Contract Terms: Competitive pricing often favors Indian and South Korean suppliers for APIs, while North American or European manufacturers may command premium pricing with stricter compliance.

Key Supply Chain Factors

• Manufacturing Capacity: Capacity growth involves investments in equipment and infrastructure to meet global demand.
• Lead Times: Typically ranges from 3 to 6 months, depending on manufacturing complexity and regulatory approvals.
• Import Restrictions: Export controls, tariffs, or local import regulations can impact availability.
• Traceability: Certificates of analysis (CoA) and batch records ensure API integrity.

Regional Supply Dynamics

• North America: Dominated by Pfizer as the original innovator, with a smaller number of approved alternative suppliers.
• Europe: Several suppliers, including Asegra Pharma and Teva, with CE and EMA approvals.
• Asia: Largest manufacturing hub for generic APIs; Indian and South Korean companies lead exports.

Disruptions and Market Trends

• API shortages have surfaced due to manufacturing delays, regulatory scrutiny,-and geopolitical issues affecting supply chains.
• Industry shifts favoring vertical integration may result in brands securing primary API sources internally or through exclusive agreements.
• Increasing regulatory stringency and inspections potentially limit raw material suppliers' entrance or retention.

Regulatory Documentation and Quality Assurance

• DMFs & CEPs: Files submitted to agencies document API manufacturing processes and compliance.
• Inspection Reports: Regular audits ensure manufacturing standards.
• Pharmacovigilance Data: Post-market data influence ongoing regulatory approval and sourcing stability.

Summary Table: API Supply Overview

Aspect	Details
Main API	Doxorubicin hydrochloride
Key Suppliers	Pfizer (original manufacturer), Hikma, Sun Pharma, Huons, Teva
Regulatory standards met	FDA, EMA, JP, MHRA, KFDA
Estimated annual global demand	Tens of thousands of grams; specific data proprietary
Supply risks	Manufacturing delays, geopolitical issues, regulatory crackdowns

Final Recommendations for Stakeholders

• Verify suppliers' regulatory documentation before procurement.
• Maintain diversified sourcing to mitigate risk.
• Monitor global API production capacity trends.
• Consider strategic stockpiling for continuity.
• Engage with suppliers early, aligned with regulatory approval processes.

---

Key Takeaways

• Major API sources include Pfizer, Hikma, Sun Pharma, Teva, and Huons.
• Supply stability hinges on compliance with quality standards, regulatory approvals, and manufacturing capacity.
• Asian manufacturers dominate global API production, offering cost-effective solutions.
• Regulatory documentation like DMFs and CEPs are essential for compliance.
• Industry trends suggest increased focus on self-sufficiency and supply chain resilience.

---

FAQs

1. What regulatory documentation is required for API sourcing?
   Suppliers should provide Certificates of Analysis (CoA), Drug Master Files (DMFs), or Certificates of Suitability (CEP) to confirm compliance.

2. How does API quality impact drug safety and efficacy?
   Consistent API quality ensures drug safety, efficacy, and regulatory compliance, reducing the risk of adverse events or recalls.

3. Are there alternative sources if primary suppliers face shortages?
   Yes, secondary suppliers or authorized generics from different regions can serve as alternatives, provided quality standards are maintained.

4. What are typical lead times for sourcing bulk API?
   Lead times range from three to six months, depending on manufacturing capacity, regulatory submissions, and shipment logistics.

5. How do regional regulations influence API sourcing?
   Export and import restrictions, customs procedures, and regional compliance requirements influence supplier choice and supply continuity.

---

References

1. U.S. Food and Drug Administration. (2022). Drug Master Files (DMF). https://www.fda.gov/cosmetics/cosmetic-products/drug-master-files-dmfs
2. European Medicines Agency. (2023). Certificate of Suitability (CEP). https://www.ema.europa.eu/en/human-regulatory/research-development/inspection-reliability-certifications/cerificates-suitability
3. IQVIA Institute. (2022). Global API Market Report.